Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new LASIK technique boost patient satisfaction and vision quality?

NCT ID NCT07087665

Symptom relief Sponsor: OVO LASIK + Lens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study looks at how satisfied people are with their vision six months after having WaveLight Plus LASIK surgery to correct nearsightedness. It also measures vision sharpness and how the surgery affects daily life. Sixty participants will fill out questionnaires and have their eyes tested to see how well the procedure works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
WaveLight Plus LASIK procedure using the WaveLight EX500 laser system
What this could lead to
If successful, this could confirm that WaveLight Plus LASIK provides high patient satisfaction and good vision quality for nearsighted people.
What could go wrong
This is a small, single-site observational study with no comparison group. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jul 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible participants will be 18 to 37 years of age and who are candidates for Wavelight Plus LASIK to correct myopia or myopic astigmatism.

Ages

18 to 37 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must be able to understand and sign an approved consent form. * Willing and able to comply with scheduled visits and other study procedures. * Age: 18 to 37 * Myopia with or without astigmatism and MRSE within the range indications for wavelight plus (myopia up to -8 D, astigmatism up to -3.0 D, S.E. more than -1.00 and up to -9.00D) * Pre-surgery BCDVA of 20/20 (0.00 logMAR) or better in each eye. * Stable refraction (within ± 0.50 D) as determined by manifest refraction spherical equivalent for a minimum of 12 months prior to surgery. * Refractive target of bilateral emmetropia * Mesopic pupil size ≥ 4.5mm * Less than 0.75 D spherical equivalent difference between Sightmap measured refraction SE and the subjective manifest refraction (MRSE) Exclusion Criteria: * Subjects with a history of previous ocular surgery. * Subjects with topographic evidence of keratoconus or ectasia. * Pre-existing retinal or corneal pathology Subjects with autoimmune diseases. * Subjects who are pregnant or nursing. * Systemic disease likely to affect wound healing, such as diabetes and severe atopy. * Any ocular disease (including uncontrolled dry eye) in which the investigator's opinion would affect the outcome of refractive surgery. * Patients with a calculated residual stromal depth \<250 µm would be excluded from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

Contacts and locations

Locations

  • Ovo Lasik + Lens

    Saint Louis Park, Minnesota, 55416, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.